【Abstract】Objective To observe the efficacy and safety of sacubitril/valsartan for the treatment of heart failure in maintenance hemodialysis patients. Methods Patients on hemodialysis complicated with chronic cardiac insufficiency and with stably controlled volume status were enrolled. They were treated with sacubitril/valsartan and followed up for 3 months. Before treatment with sacubitril/valsartan (baseline) and during follow- up, biomarkers of heart failure were tested, and volume status was assessed by body composition monitor (BCM). Changes of cardiac structure and function were examined by echocardiography. Results A total of 17 patients were included, while 4 patients withdrew due to drug-related adverse reactions and one due to renal transplantation during follow-up. Left ventricular ejection fraction (LVEF) increased from baseline 54.2±15.8% to endpoint 62.7±10.1% (t=-4.429, P=0.001) and greater improvement was found in patients with declined baseline LVEF (≤55%; t=-6.204, P=0.003), in line with a significant reduction in left ventricular end systolic volume (baseline 109.0±62.7ml vs. endpoint 79.4±52.1ml; t=4.725, P=0.009). In patients with normal LVEF, left ventricular posterior wall thickness decreased significantly (baseline 1.08 ± 0.27cm vs. endpoint
0.99 ± 0.16cm; t=3.176, P=0.025). The endpoints of serum creatinine (t=- 2.856, P=0.016), urea (t=- 3.149, P=0.009) and parathyroid hormone (baseline 328±161pg/ml vs. endpoint 409±191pg/ml; t=-2.230, P=0.048) elevated significantly as compared with the baseline values. Conclusion Sacubitril/valsartan significantly improves cardiac systolic function in hemodialysis patients with heart failure and reduces ventricular wall thickness in patients with normal LVEF. However, this treatment may also induce the increase of creatinine, urea and parathyroid hormone levels.
1. Schefold JC, Filippatos G, Hasenfuss G, et al., Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol 2016; 12(10): 610-623
2. Ganda A, Weiner SD, Chudasama NL, et al., Echocardiographic changes following hemodialysis initiation in patients with advanced chronic kidney disease and symptomatic heart failure with reduced ejection fraction. Clin Nephrol 2012; 77(5): 366-375
3. Ayus JC, Mizani MR, Achinger SG, et al., Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005; 16(9): 2778-2788
4. Roberts MA, Pilmore HL, Ierino FL, et al., The beta-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. Am J Kidney Dis 2016; 67(6): 902-911
5. Cice G, Di Benedetto A, D'Isa S, et al., Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol 2010; 56(21): 1701-1708
6. Nielsen PM, Grimm D, Wehland M, et al., The Combination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure - an Update. Basic Clin Pharmacol Toxicol 2018; 122(1): 9-18
7. Damman K, Gori M, Claggett B, et al., Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC Heart Fail 2018; 6(6): 489-498
8. Haynes R, Judge PK, Staplin N, et al., Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. Circulation 2018; 138(15): 1505-1514
9. Chang HY, Feng AN, Fong MC, et al., Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation. J Cardiol 2019; 74(4): 372-380
10. Heyse A, Manhaeghe L, Mahieu E, et al., Sacubitril/valsartan in heart failure and end-stage renal insufficiency. ESC Heart Fail 2019; 6(6): 1331-1333
11. Lee S, Oh J, Kim H, et al., Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease. ESC Heart Fail 2020; 7(3): 1125-1129
12. Rangaswami J, and McCullough PA, Heart Failure in End-Stage Kidney Disease: Pathophysiology, Diagnosis, and Therapeutic Strategies. Semin Nephrol 2018; 38(6): 600-617
13. Ponikowski P, Voors AA, Anker SD, et al., 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129-2200
14. Palmer ND, Sink KM, Smith SC, et al., Kidney disease and cognitive function: African American-diabetes heart study MIND. Am J Nephrol 2014; 40(3): 200-207
15. Hedayati SS, Bosworth HB, Kuchibhatla M, et al., The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. Kidney Int 2006; 69(9): 1662-1668
16. Cleeland CS, and Ryan KM, Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap 1994; 23(2): 129-138
17. Modolo R, de Faria AP, Ritter AM, et al., Defined daily dose (DDD) and its potential use in clinical trials of resistant hypertension. Int J Cardiol 2016; 202: 515-516
18. Jeong EM, and Dudley SC, Jr., Diastolic dysfunction. Circ J 2015; 79(3): 470-477
19. Di Lullo L, Floccari F, and Polito P, Right ventricular diastolic function in dialysis patients could be affected by vascular access. Nephron Clin Pract 2011; 118(3): c257-261
20. Ritz E, Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney Int 2009; 75(8): 771-773
21. Xu X, Hu X, Lu Z, et al., Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J Card Fail 2008; 14(9): 746-753
22. Steigerwalt S, Zafar A, Mesiha N, et al., Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis. Am J Nephrol 2007; 27(2): 159-163
23. Faul C, Amaral AP, Oskouei B, et al., FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121(11): 4393-4408
24. Kjeldsen SE, Strand A, Julius S, et al., Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy. J Clin Hypertens (Greenwich) 2006; 8(7): 487-492
25. Knowles JW, Esposito G, Mao L, et al., Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest 2001; 107(8): 975-984
26. Zile MR, Jhund PS, Baicu CF, et al., Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Circ Heart Fail 2016; 9(1): e002551
27. Sivalingam M, Vilar E, Mathavakkannan S, et al., The role of natriuretic peptides in volume assessment and mortality prediction in Haemodialysis patients. BMC Nephrol 2015; 16218
28. Joffy S, and Rosner MH, Natriuretic peptides in ESRD. Am J Kidney Dis 2005; 46(1): 1-10
29. Frieling JS, and Lynch CC, Proteolytic Regulation of Parathyroid Hormone-Related Protein: Functional Implications for Skeletal Malignancy. Int J Mol Sci 2019; 20(11): 2814
30. Ruchon AF, Marcinkiewicz M, Ellefsen K, et al., Cellular localization of neprilysin in mouse bone tissue and putative role in hydrolysis of osteogenic peptides. J Bone Miner Res 2000; 15(7): 1266-1274
31. Hagiwara H, Inoue A, Yamaguchi A, et al., cGMP produced in response to ANP and CNP regulates proliferation and differentiation of osteoblastic cells. Am J Physiol 1996; 270(5 Pt 1): C1311-1318
32. Yip CY, Blaser MC, Mirzaei Z, et al., Inhibition of pathological differentiation of valvular interstitial cells by C-type natriuretic peptide. Arterioscler Thromb Vasc Biol 2011; 31(8): 1881-1889
33. Zhang DD, Wu YF, Chen WX, et al., C-type natriuretic peptide attenuates renal osteodystrophy through inhibition of FGF-23/MAPK signaling. Exp Mol Med 2019; 51(7): 70
34. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al., The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117(12): 4003-4008
35. Krajisnik T, Bjorklund P, Marsell R, et al., Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007; 195(1): 125-131
36. Fischer HS, Zernig G, Hauser KF, et al., Neutral endopeptidase knockout induces hyperalgesia in a model of visceral pain, an effect related to bradykinin and nitric oxide. J Mol Neurosci 2002; 18(1-2): 129-134
37. Roques BP, Fournie-Zaluski MC, Soroca E, et al., The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature 1980; 288(5788): 286-288
38. Henry MS, Gendron L, Tremblay ME, et al., Enkephalins: Endogenous Analgesics with an Emerging Role in Stress Resilience. Neural Plast 2017; 20171546125
39. Nalivaeva NN, Zhuravin IA, and Turner AJ, Neprilysin expression and functions in development, ageing and disease. Mech Ageing Dev 2020; 192111363
